Uniseed
Uniseed is a venture capital firm founded in 2000 and based in Saint Lucia, Australia. Established as a joint initiative between the University of Melbourne and the University of Queensland, Uniseed focuses on investing in technology start-ups, particularly those emerging from its partner research organizations. The firm operates through multiple funds, with its latest, launched in 2015, involving the University of Sydney and CSIRO alongside its founding partners. Uniseed's investment strategy emphasizes long-term partnerships with academic institutions, providing tailored commercialization services that enhance their capabilities. The firm has made over 20 investments, typically ranging from $250,000 to $2.5 million, and has a track record of successful exits. Uniseed's commitment to supporting research commercialization is underscored by its significant contributions to the research ecosystem, which includes nearly $4 billion in research spending and numerous invention disclosures. The firm prioritizes a balanced approach to measuring success, focusing on financial returns, the establishment of viable start-ups, and the enhancement of commercialization processes for its partners.
Past deals in Australasia
Kinoxis Therapeutics
Series B in 2024
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Aravax
Series B in 2024
Aravax is an early-stage biotechnology company developing peanut allergy therapies. It uses proprietary technology to reset the immune system to tolerate peanuts without triggering allergic reactions, aiming to provide a safe and rapidly effective treatment. The company was founded in 2015 through the acquisition of intellectual property developed by Alfred Health and Monash University and is headquartered in Melbourne, Australia.
Morse Micro
Series B in 2022
Morse Micro is a wireless semiconductor company developing low-power Wi-Fi HaLow chips for the Internet of Things. Built by Wi‑Fi pioneers and industry veterans, the company focuses on long-range, energy-efficient connectivity across IoT applications such as surveillance, access control, industrial automation, and mobile devices. Its IP and patents support the design of its chips. Headquartered in Australia with offices in China and the United States, Morse Micro aims to deliver affordable, scalable IoT connectivity for a wide range of devices.
Tiny Bright Things
Seed Round in 2022
Tiny Bright Things is a Melbourne-based company founded in 2020 by Ray Dagastine and Chris Bolton. The company specializes in developing Halo microscopy technology that significantly enhances the imaging and measurement of small or transparent objects. This innovative technology serves both industrial manufacturers and researchers, particularly in fields such as agrichemicals, pharmaceuticals, nanotechnology, and life sciences. By enabling precise imaging and measurement down to the scale of viruses, drug particles, and nanotubes without altering the samples, Tiny Bright Things provides essential tools for accurate analysis at any length scale, thereby supporting advancements in scientific discovery and manufacturing processes.
OccuRx
Series B in 2022
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
Morse Micro
Series B in 2022
Morse Micro is a wireless semiconductor company developing low-power Wi-Fi HaLow chips for the Internet of Things. Built by Wi‑Fi pioneers and industry veterans, the company focuses on long-range, energy-efficient connectivity across IoT applications such as surveillance, access control, industrial automation, and mobile devices. Its IP and patents support the design of its chips. Headquartered in Australia with offices in China and the United States, Morse Micro aims to deliver affordable, scalable IoT connectivity for a wide range of devices.
Forcite Helmet Systems
Series A in 2022
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Kinoxis Therapeutics
Series A in 2020
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Ena Respiratory
Series A in 2020
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Wildlife Drones
Venture Round in 2019
Founded in 2016, Wildlife Drones specializes in designing and developing innovative animal radio-tracking systems using drones. With over two decades of experience in ecological research, the company understands the challenges in tracking highly mobile animals and has created a solution that improves signal detection and reduces labor intensity.
Aurtra
Seed Round in 2019
Aurtra Pty Ltd., established in 2016 and headquartered in Corinda, Australia, specializes in cloud-based asset management solutions for power distribution networks. The company offers a dashboard that provides real-time, fleet-wide analysis of transformers, enabling asset managers and engineers to extend transformer life, reduce capital costs, and make informed decisions regarding maintenance, replacement, and load management. Aurtra's technology, built upon a decade of research from The University of Queensland, helps mitigate catastrophic failures and improves risk management in the power distribution industry.
OccuRx
Series A in 2019
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
Morse Micro
Series A in 2019
Morse Micro is a wireless semiconductor company developing low-power Wi-Fi HaLow chips for the Internet of Things. Built by Wi‑Fi pioneers and industry veterans, the company focuses on long-range, energy-efficient connectivity across IoT applications such as surveillance, access control, industrial automation, and mobile devices. Its IP and patents support the design of its chips. Headquartered in Australia with offices in China and the United States, Morse Micro aims to deliver affordable, scalable IoT connectivity for a wide range of devices.
Agerris
Seed Round in 2019
Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.
Forcite Helmet Systems
Seed Round in 2019
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.
Wildlife Drones
Seed Round in 2019
Founded in 2016, Wildlife Drones specializes in designing and developing innovative animal radio-tracking systems using drones. With over two decades of experience in ecological research, the company understands the challenges in tracking highly mobile animals and has created a solution that improves signal detection and reduces labor intensity.
Q-Sera
Venture Round in 2018
Q-Sera develops innovative blood collection tubes using synthetically produced snake venom-derived pro-coagulant proteins. These tubes accelerate blood clotting, rapidly producing high-quality serum for biochemical analysis, thereby enhancing laboratory efficiency and patient care.
Kinoxis Therapeutics
Seed Round in 2018
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Certa Therapeutics
Grant in 2018
Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.
Kinoxis Therapeutics
Venture Round in 2018
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Cardihab
Seed Round in 2017
Cardihab Pty Ltd., established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing the need for frequent clinic visits and making the process more convenient and flexible for patients.
Brisbane Materials
Series B in 2017
Brisbane Materials Technology Pty Ltd. is an Australian manufacturer specializing in anti-reflective coatings, primarily for lighting and solar power applications. Founded in 2005 and based in St Lucia, the company emerged from the University of Queensland and has leveraged significant investment and technology development over the years. Brisbane Materials focuses on producing innovative optical coatings, including low-cost, wide-area anti-reflective coatings made from porous silica and other materials. These coatings are manufactured using a patented technology that allows for the creation of an inorganic layer from a liquid precursor at room temperature and atmospheric pressure. This process not only enhances the efficiency of solar panel covers for photovoltaic and solar thermal systems but also offers a cost-effective solution for lighting applications. As a subsidiary of XeroCoat, Brisbane Materials aims to expand its unique coating technology to a broader range of materials and applications in the future.
Ena Respiratory
Venture Round in 2017
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Smart Sparrow
Series C in 2017
Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.
OccuRx
Venture Round in 2015
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
Spinifex Pharmaceuticals
Series C in 2014
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.
Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2013
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
Hydrexia
Series B in 2013
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
Hatchtech
Venture Round in 2012
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
Spinifex Pharmaceuticals
Series B in 2011
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.
Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Verva Pharmaceuticals
Venture Round in 2011
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.
Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Smart Sparrow
Series A in 2011
Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.
Otifex
Series A in 2010
Otifex Therapeutics Pty Ltd is an Australian specialty pharmaceutical company focused on developing innovative treatments for Otitis Media with Effusion (OME), a common cause of acquired hearing loss in children. Currently, the standard treatment for OME often involves surgical insertion of grommets to regulate middle ear pressure, with no effective non-invasive alternatives available. Otifex is pioneering a novel nasal spray aimed at facilitating the natural equalization of middle ear pressure, potentially allowing OME to resolve without surgery. The company also produces nasal spray products and tablets based on betahistine, which is known for its use in treating Meniere's Disease and Vestibular Vertigo. These formulations are designed to aid in the clearance of fluid from the middle ear, offering a promising solution for children suffering from OME.
Hatchtech
Venture Round in 2010
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
Manjrasoft
Venture Round in 2009
Manjrasoft Pty. Ltd., founded in 2008 and headquartered in Melbourne, Australia, specializes in commercializing advanced grid and cloud computing technologies. The company offers Aneka, a development and management platform that facilitates rapid application development and efficient workload distribution. This platform serves various sectors, including engineering, entertainment and gaming, life sciences, and finance. Manjrasoft provides a range of solutions, such as distributed 3D rendering with Autodesk Maya, educational tools, and cloud computing consultancy services. The company's offerings are designed to enhance the performance and efficiency of software applications that require significant computational power by enabling them to operate across multiple networked computers and servers.
Verva Pharmaceuticals
Venture Round in 2009
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.
Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Fibrotech Therapeutics
Series A in 2008
Fibrotech Therapeutics is a biopharmaceutical company based in Wonga Park, Australia, focused on developing novel drug candidates aimed at treating fibrosis associated with various chronic conditions. Established in 2006, the company is dedicated to addressing unmet medical needs in diseases such as diabetic nephropathy, kidney disorders, heart failure, pulmonary fibrosis, and arthritis. Through its innovative approach, Fibrotech Therapeutics seeks to provide effective therapeutic options for patients suffering from these debilitating conditions.
Spinifex Pharmaceuticals
Series A in 2008
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.
Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex Pharmaceuticals
Series A in 2005
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.
Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2005
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
QRxPharma
Series A in 2002
QRxPharma Limited is an Australian-based pharmaceutical company focused on the research, development, and commercialization of biopharmaceutical products, particularly in pain management and abuse prevention. The company has developed a Dual Opioid platform technology, which is a patented fixed-ratio combination of morphine and oxycodone aimed at improving pain relief. Additionally, QRxPharma is known for its proprietary Stealth Beadlets technology, designed to deter drug abuse in solid dosage forms. The company's product portfolio includes both late and early-stage clinical candidates, with an emphasis on enhancing the clinical utility of approved compounds. QRxPharma has engaged in strategic partnerships for the commercialization of its lead product, immediate release MOXDUO, in various regions including the US, Canada, Australia, and South Africa. Although QRxPharma has seen changes in its operational status, it remains focused on advancing innovative solutions in pain management and abuse prevention.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.